News & Events
Check back here for regular news updates, event information and press releases.
Health Technology Wales has published guidance on laryngeal biopsy for people with suspected head and neck cancer in outpatient settings Laryngeal biopsy uses a small instrument to remove a sample of cells from the larynx so it can be examined for signs of cancer.
We’ve published the ‘Advice on Health Technologies’ bulletin to support decision making on health technologies within NHS Wales. The bulletin lists advice and guidance published by us and other health technology assessment (HTA) agencies across the UK and Europe from April to June 2022.
A search has begun for digital solutions to the biggest challenges facing the Welsh health and social care sectors today. Health Technology Wales (HTW) has launched a digital open topic call in a bid to identify the next big digital health technologies for Wales.
Health Technology Wales has published guidance recommending the routine adoption of stereotactic ablative radiotherapy (SABR) to treat people with primary kidney cancer who are not suitable for surgery or other ablative techniques.
Health Technology Wales has published guidance recommending that health boards across Wales should adopt electronic blood management systems (EBMS) to support blood transfusions.
HTW has published its latest Impact Report which summaries its achievements as a national health technology assessment organisation in 2021. We would like to thank the stakeholders that collaborated with us throughout 2021 and enabled us to continuing assessing technologies that will have a significant impact on health and social care services in Wales.
An exciting opportunity has arisen for two Health Services Researchers to join Health Technology Wales (HTW). We are seeking to recruit two Health Services Researchers as part of our work for the Wales COVID-19 Evidence Centre.
Radiotherapy that can halve the time patients with prostate cancer spend receiving treatment is recommended for use in Wales
A form of radiotherapy that could halve the time prostate cancer patients spend receiving treatment has been recommended for use in Wales. Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate cancer.